
Nine Square Therapeutics is focused on developing innovative small-molecule therapeutics for neurodegenerative diseases such as Parkinson's disease and ALS. By leveraging advanced computational chemistry, biophysics, and machine learning, the company aims to identify and optimize drug candidates targeting previously undruggable pathways. Founded in 2020, Nine Square is committed to reshaping the treatment landscape for debilitating conditions through a unique approach that combines experimental biology with computational modeling. The company is building a diversified portfolio of first-in-class drug candidates and has received significant funding to advance its research and development efforts.

Nine Square Therapeutics is focused on developing innovative small-molecule therapeutics for neurodegenerative diseases such as Parkinson's disease and ALS. By leveraging advanced computational chemistry, biophysics, and machine learning, the company aims to identify and optimize drug candidates targeting previously undruggable pathways. Founded in 2020, Nine Square is committed to reshaping the treatment landscape for debilitating conditions through a unique approach that combines experimental biology with computational modeling. The company is building a diversified portfolio of first-in-class drug candidates and has received significant funding to advance its research and development efforts.
Founded: 2020
Headquarters: South San Francisco, CA
Focus: Small-molecule therapeutics for movement and neurodegenerative disorders (e.g., Parkinson's, ALS)
Platform: Phenotypic image-based cell profiling, computational molecular modeling, chemistry, machine learning
Notable backers: Apple Tree Partners; Michael J. Fox Foundation
Movement disorders and neurodegenerative diseases (Parkinson's disease, ALS).
2020
Biotechnology
50000000
Launched with $50M in committed Series A funding from Apple Tree Partners.
Reported grant support from the Michael J. Fox Foundation.
“Backed/ incubated by life-sciences VC Apple Tree Partners; grant support from disease-focused foundation Michael J. Fox Foundation”